Pharming Group N.V. PHG.F · Stock Open Pharming Group N.V. in new tab
Pharming Group N.V. Analysis (PHG.F)
Is Pharming Group N.V. a good investment? Pharming Group N.V. (PHG.F) is currently trading at 9.80 EUR.
In terms of valuation, the stock trades at a P/E ratio of 80.00. This high multiple suggests investors have priced in significant future growth expectations.
Investor FAQ
Does Pharming Group N.V. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Pharming Group N.V.?
Pharming Group N.V. is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.
Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Community Discussion